[Skip to Content]
[Skip to Content Landing]
Views 237
Citations 0
Editorial
June 21, 2017

Evaluating Evolving Technologies in a Time of Rapid ChangeThe Case of Transcatheter Aortic Valve Replacement

Author Affiliations
  • 1Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina
  • 2Duke Clinical Research Institute, Durham, North Carolina
  • 3Verily Life Sciences, South San Francisco, California
  • 4Department of Medicine, Stanford University, Stanford, California
JAMA Cardiol. Published online June 21, 2017. doi:10.1001/jamacardio.2017.1733

Percutaneous treatment of valvular heart disease is a modern miracle. A decade ago, it was inconceivable to all but a few visionary inventors that a catheter–based approach could be used to replace a cardiac valve, thus eliminating the need for a thoracotomy with all of its associated costs, inconvenience, and potential for major adverse outcomes. But following approval by the US Food and Drug Administration (FDA) and payer reimbursement for the procedure, transcatheter aortic valve replacement (TAVR) is now widely used in clinical practice in the United States and worldwide.

First Page Preview View Large
First page PDF preview
First page PDF preview
×